Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification

被引:0
作者
Motaz Ashkar
Shruti Chandra
Santhi Swaroop Vege
Hiroaki Takahashi
Naoki Takahashi
Robert R. McWilliams
机构
[1] Washington University in Saint Louis,Division of Gastroenterology
[2] Mayo Clinic,Division of Gastroenterology
[3] Mayo Clinic,Department of Radiology
[4] Mayo Clinic,Division of Oncology
来源
Cancer Immunology, Immunotherapy | 2023年 / 72卷
关键词
Amylase; Immune checkpoint inhibitors; Immune-related adverse events; Lipase; Pancreatitis;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:895 / 901
页数:6
相关论文
共 121 条
[1]  
Vege SS(2018)Initial medical treatment of acute pancreatitis: American gastroenterological association institute technical review Gastroenterology 154 1103-1139
[2]  
DiMagno MJ(2018)American gastroenterological association institute guideline on initial management of acute pancreatitis Gastroenterology 154 1096-1101
[3]  
Forsmark CE(2013)Classification of acute pancreatitis–2012: revision of the Atlanta classification and definitions by international consensus Gut 62 102-111
[4]  
Martel M(2019)Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury J Immunother Cancer 7 31-236
[5]  
Barkun AN(2017)Thinking critically about classifying adverse events: incidence of pancreatitis in patients treated with nivolumab + ipilimumab J Natl Cancer Inst 109 djw260-723
[6]  
Crockett SD(2019)Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study J Clin Med Res 11 225-575
[7]  
Wani S(2010)Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 711-111
[8]  
Gardner TB(2015)Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities Transl Lung Cancer Res 4 560-398
[9]  
Falck-Ytter Y(2020)Workup and management of immune-mediated hepatobiliary pancreatic toxicities that develop during immune checkpoint inhibitor treatment Oncologist 25 105-552
[10]  
Barkun AN(2017)Gastrointestinal and hepatic complications of immune checkpoint inhibitors Curr Gastroenterol Rep 19 3-85